{
    "nctId": "NCT02767661",
    "briefTitle": "Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer",
    "officialTitle": "A Phase 3 Randomized Controlled Study of Metronomic Capecitabine Combined With Aromatase Inhibitor Versus Aromatase Inhibitor Alone for First Line Treatment in Hormone Receptor-positive, Her2-negative Metastatic Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 240,
    "primaryOutcomeMeasure": "Progress-free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult women with locoregionally recurrent or metastatic disease not amenable to curative therapy\n* Confirmed diagnosis of ER positive/Her2-negative breast cancer\n* No prior systemic anti-cancer therapy for locoregionally recurrent or metastatic disease\n* Any menopausal status, but premenopausal or perimenopausal patients are required to receive LHRHa treatment\n* Measurable disease defined by RECIST version 1.1, or bone-only disease\n* Eastern Cooperative Oncology Group (ECOG) 0-2, and life expectancy \u2265 3 months\n* Adequate organ and marrow function\n* Resolution of all toxic effects of prior therapy or surgical procedures\n\nExclusion Criteria:\n\n* Patients who have progressed within 2 years of adjuvant endocrine therapy\n* Patients who have not received prior endocrine therapy and are eligible to receive fulvestrant as initial therapy\n* Patients with advanced, symptomatic, visceral spread that are at risk of life threatening complication in the short term\n* Known uncontrolled or symptomatic central nervous system metastases\n* Diagnosis of any other malignancy within 3 years prior to randomization (except adequately treated basal or squamous cell skin cancer or cervical carcinoma in situ)\n* Serious uncontrolled intercurrent infections or intercurrent medical or psychiatric illness",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}